Microparticles and Applications in Assays and Endpoints

Microparticles are 100 – 1000 nm subcellular bodies released during apoptosis, cell injury or cellular activation. Serum, plasma, synovial fluid, CSF and other biofluid-derived circulating microparticles have been increasingly suggested as meaningful matrices for biomarker assay development.

Originating from a variety of cells including endothelium, platelets, and synoviocytes, microparticles maintain features of their parent cells including surface elements, some intracellular organelles and miRNA. Recent publications have described microparticle quantity and quality as indicators of cardiovascular/myocardial infarction risk, metastatic tumor status, inflammatory status and endothelial dysfunction.

The Covance Biomarker Center of Excellence has seen an increasing number of requests for microparticle quantitation and/or characterization in drug discovery and development studies. However, there remains much to learn about this material and its use as a matrix for routine biomarker measurement.

This webinar will focus on Covance's experience in standardization of methods for microparticle isolation from preclinical and clinical samples, as well as recent findings from microparticle analyses in disease models of oncology and cardiovascular/metabolic disease. Finally, opportunities for the use of microparticles as translational biomarkers spanning the drug discovery to drug development interface will be discussed.
Date: Tuesday, October 29, 2013 
Time: 11am - 12am EDT / 3pm - 4pm GMT (UK) / 4pm - 5pm CET (EU-Central
Duration: 1 hour

Who should attend?
BioPharma decision makers working in biosimilar development

By clicking the "Register Now" button you submit your information to the Webinar organizer, who will use it to communicate with you regarding this event and their other services.
Copyright © 2013 Covance Inc. All rights reserved.
Katherine T. Landschulz, PhD
Manager, Biomarker Center of 
Excellence, Covance

About Katherine

Dr. Landschulz received her PhD in Human Genetics/Biology from Johns Hopkins University, Baltimore, Maryland and has over 15 years of experience working in pharmaceutical research and development. She has lead drug discovery, genomic and proteomic biomarker discovery, translational medicine and pharmacogenomic efforts. Dr. Landschulz joined Covance in 2010 as Principal Scientist/Cardiovascular, Metabolic Disease Therapeutic Area lead and and is currently Manager of the Biomarker Center of Excellence Assay Production team. She has been exploring the use of microparticles as biomarkers in models of oncology, cardiovascular disease and diabetes for the past 3 years.